This peptide stimulates the release of growth hormone without affecting cortisol levels, making it a unique and valuable tool for research endeavors
Diabetes 51 , S434442 (2002)
Afamelanotide (Scenesse, Clinuvel Pharmaceuticals) is a linear MC1R selective tridecapeptide, approved by the FDA on October 8, 2019, and by the EMA on December 22, 2014, exclusively for the treatment of erythropoietic protoporphyria (EPP) in adults
Individuals closer to a healthy BMI also tend to lose a higher proportion of fat-free mass (which includes muscle) compared to those with more body fat to lose
Cardiovascular system response Melanotan peptide may have adverse effects on the cardiovascular system, including the following: Elevated blood pressure: Melanotan peptide may activate the sympathetic nervous system, leading to an increase in blood pressure
(2025, Olympia) Safety Concerns Compounded GLP1s lack the FDA approval that commercially manufactured drugs undergo, meaning they may not have been subjected to the same rigorous testing for safety and efficacy